tbuckley/cabot-search huggingface dataset:
PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC
Authors: Dinesh Khanna, Celia J. F. Lin, Jonathan Goldin, Grace Kim, Masataka Kuwana, Yannick Allanore, Anastas Batalov, Irena Butrimiene, Patricia Carreira, Marco Matucci-Cerinic, Oliver Distler, Dušanka Martinović Kaliterna, Carina Mihai, Mette Mogensen, Marzena Olesińska, Janet Pope, Gabriela Riemekasten, Tatiana Sofía Rodriguez-Reyne, Maria Jose Santos, Jacob M. van Laar, Helen Spotswood, Jeffrey Siege, Angelika Jahreis, Daniel Furst, Christopher Denton
Journal: Annals of the Rheumatic Diseases (2019)
Trans and non-binary pregnancy, traumatic birth, and perinatal mental health: a scoping review
Authors: Mari Greenfield, Zoe Darwin
Journal: International Journal of Transgender Health (2020)

Background: Many trans and non-binary people wish to be parents. However, few countries record figures for trans and non-binary people becoming pregnant/impregnating their partners. Pregnant non-binary people and trans men may be growing populations, with heightened vulnerabilities to traumatic birth and perinatal mental health difficulties (i.e. pregnancy-one year postpartum). Aim: To conduct a scoping review on traumatic birth and perinatal mental health in trans and non-binary people to identify research evidence, summarize findings, and identify gaps. Methods: Electronic databases were searched to identify published English-language evidence. Eligibility was not restricted by type of study, country, or date. Findings: All studies were from the Global North and most participants were white. The literature focuses on structural and psychological barriers faced by non-binary people and trans men and on the lack of reliable medical information available. There is a lack of empirical research and, to date, no research into trans and non-binary parents' experiences has focused on traumatic birth or perinatal mental health. However, common themes of dysphoria, visibility, isolation, and the importance of individualized respectful care indicate potential vulnerability factors. Trans women's and non-binary people's experiences are particularly under-researched. Discussion: The themes of dysphoria, visibility, and isolation present a series of challenges to pregnant non-binary people and trans men. These coalesce with external events and internal choices, creating the potential to make the individual feel not man enough, not trans enough, not pregnant enough, and not safe enough during pregnancy, birth, and the postpartum. Further research involving trans people is needed to inform future services.
Lncrna-Iκbα Promotes Erythroid Differentiation By Inhibiting NF-Κb Pathway As a Cerna Against Mir-24-3p in Polycythemia Vera
Authors: Zhigang Li, Xuemei Fu, Zhixiang Zuo, Fangfang Sun, Xiaojun Zhang, Jieping Chen, Yu Hou
Journal: Blood (2020)
Abstract 539: Buthionine Sulfoximine (BSO) Prevents Reductive Stress-induced Pathological Hypertrophic Cardiomyopathy
Authors: Gobinath Shanmugam, Silvio Litovsky, Steven M Pogwizd, Namakkal S. Rajasekaran
Journal: Circulation Research (2020)

Background: Chronic reductive stress (RS) induces pathological cardiac remodeling and diastolic dysfunction. Here, we hypothesized that preventing RS via glutathione (GSH) depletion, through selective inhibition of γ-glutamyl cysteine ligase (γGCL), mitigates cardiac pathology in cRS mice. Methods: Cardiac-specific constitutively active Nrf2 TG-mice (α-MHc-caNrf2-TG), at 6 weeks of age, were administered with buthionine sulfoximine (BSO; 5.0 mM/Kg; daily for 16-weeks). At the end of 22 weeks, cardiac structure and function (systole &amp; diastole using echocardiography), myocardial redox state, levels of ROS (using dihydroethidium (DHE) fluorescence), and antioxidant proteome were assessed in TG mice treated with PBS or BSO and compared with the age matched NTG littermates (n=6/group). Results: While the TG mice experiencing RS (GSH; 426.3±22.55 vs. 141.8±3.9 &amp; GSH/GSSG; 61.04±5.4 vs. 23.27±1.3 in TG vs. NTG), this was significantly curtailed in BSO-treated TG mice (GSH 161.8±12.6 &amp; GSH/GSSG; 25.1±4.3). This was coupled with the normal cardiac functions (EF; ~53% &amp; MV E/A; 1.57) in the BSO-treated TG when compared to TG mice experiencing a hyper systolic function (&gt;80% ejection fraction) with decreased cardiac volume and diastolic dysfunction with restricted filling (MV E/A ratio; &gt;3.0), Of note, BSO treatment did not alter the protein levels of antioxidants (i.e. GCLC, GCLM, NQO1 and CAT), but only depleted the GSH pool (via inhibiting GCL activity) and restored the basal ROS signaling in the myocardium. Moreover, the BSO-treated TG mice did not develop cardiac hypertrophy, which was assessed by heart weight/body weight ratio, qPCR-based gene expression for hypertrophy ( Anf, Bnf, α-MHc and β-Mhc ). Conclusion: Our results suggest that pharmacological manipulation of myocardial redox and repletion of basal ROS signaling prevented RS-mediated pathological processes and rescued the cardiac structure and function.
Study of the Role of Splicing Factor SRRM2 in Cytarabine Treatment Resistance in Acute Myeloid Leukemia
Authors: María Luz Morales, Roberto Garcia-Vicente, Noemí Álvarez Sánchez-Redondo, Alba Rodríguez García, Alejandra Ortiz-Ruiz, Armando Reyes-Palomares, Sylvie Hermouet, Rosa Ayala, Joaquin Martinez-Lopez, María Linares
Journal: Blood (2020)
Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial
Authors: Roch Houot, Viola Poeschel, Bettina Altmann, Thomas Illmer, Marc André, Martin Dreyling, Herve Maisonneuve, Herve Tilly, Stephanie Mayer, Rene-Olivier Casasnovas, Steven Le Gouill, Fritz C. Offner, Guillaume Cartron, Andrea Kerkhoff, Thomas Weber, Joerg Hoffmann, Marita Ziepert, Wolfram Klapper, Emmanuel Itti, Dirk Hellwig, Laurence De Leval, Andreas Rosenwald, Corinne Haioun, Laurent Dercle, Philippe Gaulard, Gerhard Held
Journal: Blood (2020)
Chromosomal Abnormalities in MDS Are Linked to Dysregulation of CDC20 and CEP55 Genes
Authors: Mayara Magna de Lima Melo, Daniela de Paula Borges, Antônio Wesley Araújo Dos Santos, Gabrielle Melo Cavalcante, Leticia Rodrigues Sampaio, Roberta Taiane Germano Oliveira, Silvia Maria Meira Magalhães, Ronald Feitosa Pinheiro
Journal: Blood (2020)
Parallel Social Information Processing Circuits Are Differentially Impacted in Autism
Authors: Eastman M. Lewis, Genevieve L. Stein-O’Brien, Alejandra V. Patino, Romain Nardou, Cooper D. Grossman, Matthew Brown, Bidii Bangamwabo, Ndeye Ndiaye, Daniel Giovinazzo, Ian Dardani, Connie Jiang, Loyal A. Goff, Gül Dölen
Journal: Neuron (2020)
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse
Authors: Hind Rafei, Hagop M. Kantarjian, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Joseph D. Khoury, Sa A Wang, Jeffrey L. Jorgensen, Issa F. Khouri, Partow Kebriaei, Nitin Jain, Bouthaina S. Dabaja, Yesid Alvarado, Tapan M. Kadia, Shilpa Paul, Serena Chew, Guillermo Garcia-Manero, Jan A. Burger, Courtney D. DiNardo, Naval Daver, Guillermo Montalban-Bravo, Musa Yilmaz, Maro Ohanian, Maria Khouri, Philip A. Thompson, Jovitta Jacob, Meagan Rostykus, Rebecca Garris, Marina Konopleva, Susan M. O'Brien, Elias Jabbour
Journal: Blood (2020)
Hydroxyurea to Reduce Stroke Risk in Tanzanian Children with Sickle Cell Anemia
Authors: Emmanuela E. Ambrose, Luke R. Smart, Primrose Songoro, Idd Shabani, Protas Komba, Mwesige Charles, Thad A. Howard, Susan E. Stuber, Adam Lane, Teresa Latham, Abel Nkono Makubi, Russell E. Ware
Journal: Blood (2020)
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B
Authors: Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Fabien Zoulim, Juneyoung Lee, Jung‐Hwan Yoon
Journal: Hepatology (2020)

Background and Aims Long‐term antiviral therapy can effectively suppress viral replication and improve clinical outcomes in patients with chronic hepatitis B (CHB), but it cannot eliminate risk of HCC. We investigated the association of metabolic risk factors with the risks of cancer and all‐cause mortality in patients with CHB. Approach and Results This nationwide population‐based study from the Korean National Health Insurance Service database consisted of adults with CHB who underwent health examinations from 2007 through 2012. We collected baseline data on metabolic risk factors, including obesity, high blood pressure, hypercholesterolemia, and diabetes. The risks of developing HCC, non‐HCC cancer, and overall death were analyzed according to the metabolic risk profile. The study population composed of 317,856 patients (median age, 46 years [interquartile range, 37‐54 years]; 219,418 men [69.0%]) had 2,609,523.8 person‐years of follow‐up. A total of 18,850 HCCs, 22,164 non‐HCC cancers, and 15,768 deaths were observed during a median follow‐up period of 8.5 years. The metabolic risk factor burden was positively associated with the risks of HCC, non‐HCC cancer, and all‐cause mortality (all P &lt; 0.0001 for trend). Patients with ≥3 metabolic risk factors, compared with those without metabolic risk factors, showed adjusted hazard ratios of 1.23 (95% CI, 1.16‐1.31) for HCC, 1.34 (95% CI, 1.27‐1.41) for non‐HCC cancer, and 1.31 (95% CI, 1.23‐1.39) for all‐cause mortality. Among patients receiving antiviral therapy for over 5 years, the risk‐increasing association of the sum of metabolic risk factors with the risks of HCC and overall death was consistent. Conclusion The metabolic risk factor burden was associated with increased risks of HCC, non‐HCC cancer, and all‐cause mortality in patients with CHB.
Multi-Parameter Neurological Study Based on Combined Conventional and Functional Assessments in Gaucher Disease Patients (SENOPRO_GAUCHER Study)
Authors: Emanuele Cerulli Irelli, Carlo Di Bonaventura, Gianmarco Tessari, Tiziana Di Pippo, Rosaria Turchetta, Stefano Ferracuti, Anna Teresa Giallonardo, Rocco Plateroti, Luisa Cardarelli, Daniela De Benedittis, Sara Mohamed, Giovanna Palumbo, Francesca Caramia, Marcella Nebbioso, Patrizia Mancini, Fiorina Giona
Journal: Blood (2020)
E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies
Authors: Thomas A. Wills, Samir S. Soneji, Kelvin Choi, Ilona Jaspers, Elizabeth K. Tam
Journal: European Respiratory Journal (2020)

Use of electronic cigarettes (e-cigarettes) is prevalent among adolescents and young adults, but there has been limited knowledge about health consequences in human populations. We conduct a systematic review and meta-analysis of results on respiratory disorders from studies of general-population samples and consider the mapping of these results to findings about biological processes linked to e-cigarettes in controlled laboratory studies.We conducted a literature search and meta-analysis of epidemiological studies on the association of e-cigarette use with asthma and with COPD. We discuss findings from laboratory studies about effects of e-cigarettes on four biological processes: cytotoxicity, oxidative stress/inflammation, susceptibility to infection and genetic expression.Epidemiological studies, both cross-sectional and longitudinal, show a significant association of e-cigarette use with asthma and COPD, controlling for cigarette smoking and other covariates. For asthma (n=15 studies), the pooled adjusted odds ratio (aOR) was 1.39 (95% CI 1.28-1.51); for COPD (n=9 studies) the aOR was 1.49 (95% CI 1.36-1.65). Laboratory studies consistently show an effect of e-cigarettes on biological processes related to respiratory harm and susceptibility to illness, with e-cigarette conditions differing significantly from clean-air controls, although sometimes less than for cigarettes.The evidence from epidemiological studies meets established criteria for consistency, strength of effect, temporality, and in some cases a dose-response gradient. Biological plausibility is indicated by evidence from multiple laboratory studies. We conclude that e-cigarette use has consequences for asthma and COPD, which is of concern for respirology and public health.
Safety and Efficacy of Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Authors: Farwah N. Fatima, Faiz Anwer, Muhammad Ashar Ali, Muhammad Yasir Anwar, Sana Khan, Rimsha Ali, Wajeeha Aiman, Anum Javaid, Aqsa Mumtaz, Nayab Mirza, Hamza Hashmi
Journal: Blood (2020)
Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma
Authors: Jianbiao Zhou, Sabrina Hui Min Toh, Kalpnaa Balan, Tze King Tan, Yunlu Jia, Jing Quan Lim, Choon Kiat Ong, Soon Thye Lim, Tuan Zea Tan, Siok-Bian Ng, Takaomi Sanda, Wee-Joo Chng
Journal: Blood (2020)
Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma
Authors: Yaya Chu, Gaurav Nayyar, Nang Kham Su, Jeremy M Rosenblum, Patrick Soon-Shiong, John Lee, Jeffrey T Safrit, Matthew Barth, Dean Lee, Mitchell S Cairo
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background The prognosis of patients with relapsed or progressive B cell (CD20 + ) non-Hodgkin’s lymphoma (B-NHL), including Burkitt lymphoma (BL), is dismal due to chemoradiotherapy resistance. Novel therapeutic strategies are urgently needed. N-820 is a fusion protein of N-803 (formerly known as ALT-803) to four single-chains of rituximab. This agent has tri-specific binding activity to CD20 and enhanced antibody-dependent cell-mediated cytotoxicity. Methods We investigated the anti-tumor combinatorial effects of N-820 with ex vivo expanded peripheral blood natural killer (exPBNK) cells against rituximab-sensitive and rituximab-resistant CD20 + BL in vitro using cytoxicity assays and in vivo using human BL xenografted NOD/SCID/IL2rγnull (NSG) mice. We also investigated the cytokines/chemokines/growth factors released using ELISA and multiplex assay. Gene expression changes were examined using real-time PCR arrays. Results N-820 significantly enhanced the expression of NK activating receptors (p&lt;0.001) and the proliferation of exPBNK cells with enhanced Ki67 expression and Stat5 phosphorylation (p&lt;0.001). N-820 significantly enhanced the secretion of cytokines, chemokines, and growth factors including GM-CSF, RANTES, MIP-1B (p&lt;0.001) from exPBNK cells as compared with the combination of rituximab+N-803. Importantly, N-820 significantly enhanced in vitro cytotoxicity (p&lt;0.001) of exPBNK with enhanced granzyme B and IFN-γ release (p&lt;0.001) against BL. Gene expression profiles in exPBNK stimulated by N-820+Raji-2R showed enhanced transcription of CXCL9 , CXCL1 , CSF2 , CSF3 , GZMB, and IFNG . Moreover, N-820 combined with exPBNK significantly inhibited rituximab-resistant BL growth (p&lt;0.05) and extended the survival (p&lt;0.05) of BL xenografted NSG mice. Conclusions Our results provide the rationale for the development of a clinical trial of N-820 alone or in combination with endogenous or ex vivo expanded NK cells in patients with CD20 + B-NHL failing prior rituximab containing chemoimmunotherapy regimens.
Declines in SARS-CoV-2 Transmission, Hospitalizations, and Mortality After Implementation of Mitigation Measures— Delaware, March–June 2020
Authors: Florence A. Kanu, Erica E. Smith, Tabatha Offutt-Powell, Rick Hong, Thu-Ha Dinh, Eric Pevzner
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Mitigation measures, including stay-at-home orders and public mask wearing, together with routine public health interventions such as case investigation with contact tracing and immediate self-quarantine after exposure, are recommended to prevent and control the transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1-3). On March 11, the first COVID-19 case in Delaware was reported to the Delaware Division of Public Health (DPH). The state responded to ongoing community transmission with investigation of all identified cases (commencing March 11), issuance of statewide stay-at-home orders (March 24-June 1), a statewide public mask mandate (from April 28), and contact tracing (starting May 12). The relationship among implementation of mitigation strategies, case investigations, and contact tracing and COVID-19 incidence and associated hospitalization and mortality was examined during March-June 2020. Incidence declined by 82%, hospitalization by 88%, and mortality by 100% from late April to June 2020, as the mask mandate and contact tracing were added to case investigations and the stay-at-home order. Among 9,762 laboratory-confirmed COVID-19 cases reported during March 11-June 25, 2020, two thirds (6,527; 67%) of patients were interviewed, and 5,823 (60%) reported completing isolation. Among 2,834 contacts reported, 882 (31%) were interviewed and among these contacts, 721 (82%) reported completing quarantine. Implementation of mitigation measures, including mandated mask use coupled with public health interventions, was followed by reductions in COVID-19 incidence and associated hospitalizations and mortality. The combination of state-mandated community mitigation efforts and routine public health interventions can reduce the occurrence of new COVID-19 cases, hospitalizations, and deaths.
Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)
Authors: Sudipto Mukherjee, Xiting Cao, Islam Sadek, Rodrigo Maegawa, Dominick Latremouille-Viau, Irina Pivneva, Annie Guérin, B. Douglas Smith
Journal: Blood (2020)
Abstract 379: Metformin Induces Energetic Reprogramming in Human Cardiomyocytes
Authors: Larisa Emelyanova, Yasheng Yan, Stacie Kroboth, Catherine Warner, David Kress, Farhan Rizvi, Xiaowen Bai, Arshad Jahangir
Journal: Circulation Research (2020)

Introduction: Metformin (Metf) is an oral hypoglycemic agent widely used to treat type 2 diabetes. It also lessens myocardial injury and reduces cardiovascular mortality. However, the exact molecular mechanisms of Metf therapeutic action in the human heart remain obscure. The aim of this study was to evaluate the cardioprotective effect of Metf on cardiomyocytes derived from human-induced pluripotent stem cells (hiPSC-CMs). Methods: The hiPSC-CMs were derived from an hiPSC line generated from human dermal fibroblasts and treated with Metf (0-20 mM) for 24 hours. Oxygen consumption rate (OCR) was measured using XF96 Extracellular Flux Analyzer. Metabolites were profiled using a liquid chromatography coupled to tandem mass spectrometry. Tukey’s pairwise comparison and one-way ANOVA were applied for comparison between groups. P &lt; 0.05 was considered significant. Results: At concentrations ≤ 2.5 mM, Metf significantly enhanced the cellular OCR (Fig. A) and enhanced mitochondrial biogenesis (Fig. B) via AMPK signaling (Fig. C). This effect was abrogated by compound C, an inhibitor of AMPK. At concentrations &gt; 5 mM, Metf reduced the cellular OCR and activated glycolysis (Fig. D) and glutaminolysis (Fig. E) in the cardiomyocytes. Conclusion: Thus, in the human heart, Metf might improve cardioprotection owing to its dual effect on mitochondria. At low doses, it activates mitochondrial biogenesis via AMPK signaling and increases the OCR. At high doses, it causes metabolic reprogramming by enhancing glycolysis and glutaminolysis as a compensatory mechanism in response to inhibition of the mitochondrial oxidative phosphorylation.
Abstract 443: Blockade of the Thromboxane/prostanoid Receptor Prevents ECG Abnormalities in RV Pressure Overload
Authors: Erica J Carrier, Kyungsoo KIM, Sheila Shay, Christy Moore, Bjorn C Knollmann, James D West
Journal: Circulation Research (2020)

The increased afterload of pulmonary arterial hypertension (PAH) impairs right ventricular function and ultimately leads to failure, as the RV struggles to adapt to increased pressure with remodeling and fibrosis. During PAH, cardiomyocytes upregulate cell-surface expression of the G protein-coupled thromboxane/prostanoid receptor (TPr). Increased myofibroblast and immune cell populations may also contribute to the enhanced TPr expression seen in the PAH RV. Activation of the cardiomyocyte TPr increases intracellular calcium via G αq /IP 3 ; activation of the receptor in other cells leads to fibrosis and vasoconstriction. Preventing signaling through the TPr prevents RV fibrosis in murine models of PAH without affecting arterial pressure. Because infusion of TPr agonist can cause arrhythmia in anesthetized rabbits, and we have previously found that RV pressure overload causes sustained increases in end-diastolic calcium in RV cardiomyocytes that is blocked with TPr antagonist, we hypothesized that endogenous TPr activation can lead to conduction abnormalities in RV pressure overload. Here, we used pulmonary arterial banding (PAB) of female mice to induce fixed pressure overload of the RV. Sham-operated or PAB mice were treated with normal drinking water or water containing 25 mg/kg/day of the TPr antagonist ifetroban and were evaluated at 4 weeks past PAB. RV ejection fraction was similarly depressed in vehicle- and antagonist-treated mice, although spontaneous running, RV fibrosis, and RV relaxation time were improved in PAB mice given ifetroban. ECG abnormalities in PAB mice confirmed a prolonged relaxation and suggested delays in repolarization. These were abolished with TPr antagonism. PAB altered RV expression and localization of connexin-43 (Cx43) in vehicle-treated, but not ifetroban-treated mice. Cx43 derangement is associated with impaired cell-to-cell electrical conduction and impulse propagation. Compiled, our findings suggest that endogenous TPr activation produces alterations in RV calcium handling, signaling, and cell-cell junctions that contribute to early failure in pressure overload. Therapeutic TPr antagonism may prevent this deleterious remodeling and prolong survival in patients with PAH.
Abstract 14045: Echocardiographic Characteristics of Peripartum Cardiomyopathy Compared to Preeclampsia
Authors: Bassman Tappuni, Ali AlKhayru, Belal Kaseer, Freidoon Ghazi, John Wilson, William T Schnettler, Kathleen L Smith, Jenni Steinbrunner, Kamal Shemisa
Journal: Circulation (2019)

Introduction: Pregnancy related heart disease is prevalent and exhibits significant morbidity. Peripartum Cardiomyopathy (PPCM) & Preeclampsia (PEc) are two conditions with similar clinical present...
Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
Authors: Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean Jacques Kiladjian
Journal: Blood (2020)
Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy
Authors: Noemie Leblay, Ranjan Maity, Elie Barakat, Sylvia McCulloch, Peter Duggan, Victor Jimenez-Zepeda, Nizar J. Bahlis, Paola Neri
Journal: Blood (2020)
Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells
Authors: Wenxue Ma, Larissa Balaian, Phoebe Mondala, Yudou He, Cayla Mason, Jessica Pham, Jeremy Lee, Raymond Diep, Sanja Coso, Kathleen Fisch, Adam Mark, Sheldon Morris, Qingfei Jiang, Thomas Whisenant, Aleksandra Rizo, Fei Huang, Mary Donohoe, Ludmil Alexandrov, Catriona Jamieson
Journal: Blood (2020)